Results 81 to 90 of about 208,148 (266)

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]

, 2011
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem, Abdul Qayyum, Abid Jamil, Abid Taj, Ahmad Khalid, Ammara Tahir, Ijaz Shah, Mahwish Khan, Mubashar Naqvi, Mudassar Iqbal, Muhammad Abbad, Muhammad Ferhan, Muhammad Khalid, Najeeb ur-Rehman, Riaz ul-Haq, Shahid Baig, Tanveer Akhtar, Tariq Gill, Weng Qin, Zafar Iqbal   +19 more
core   +1 more source

Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML [PDF]

, 1991
Between 1985 and 1989, many cases of Philadelphia (Ph) chromosome negative chronic myelogenous leukemia (CML) were reported. For this review, the following selection criteria were used: the original articles on Ph-negative cases should provide clinical ...
Grosveld, G.C. (Gerard), Hagemeijer, A. (Anne), Plas, D. (D.) van der   +2 more
core   +1 more source

Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil

Revista Brasileira de Hematologia e Hemoterapia, 2015
Objective: To evaluate trends in mortality among adults with myeloid leukemia in the Vale do Paraíba, State of São Paulo. Methods: Data from the Brazilian National Health Service database DATASUS provided the number of deaths caused by myeloid leukemia ...
Fernando Callera, Alexandra Fernandes Callera, Evandro Secchi Rosa   +2 more
doaj   +1 more source

Clinical implications of discordant early molecular responses in CML patients treated with imatinib [PDF]

, 2019
A reduction in BCR-ABL1/ABL1IS transcript levels to <10% after 3 months or <1% after 6 months of tyrosine kinase inhibitor therapy are associated with superior clinical outcomes in chronic myeloid leukemia (CML) patients.
Accurso V., Antolino A., Di Raimondo F., Forte S., Impera S., Malato A., Mannina D., Manzella L., Martino B., Massimino M., Mineo G., Musolino C., Musso M., Pennisi M. S., Porretto F., Russo S., Siragusa S., Spitaleri A., Stagno F., Stella S., Tirro E., Vigneri P., Vitale S. R., Zammit V.   +23 more
core   +1 more source

Navigating PROTACs in Cancer Therapy: Advancements, Challenges, and Future Horizons

Food Science &Nutrition, Volume 13, Issue 2, February 2025.
Illustrating the mechanism of Proteolysis Targeting Chimeras (PROTACs), development of ligands available for PROTACs, PROTACs targeting cancers, and its advantages. PROTACs offer a versatile strategy for personalized cancer treatment ABSTRACT Proteolysis Targeting Chimeras (PROTACs) have revolutionized cancer therapy by offering a selective and ...
Saooda Ibrahim, Muhammad Umer Khan, Iqra Khurram, Raima Rehman, Abdur Rauf, Zubair Ahmad, Abdullah S. M. Aljohani, Waleed Al Abdulmonem, Mohammed Mansour Quradha   +8 more
wiley   +1 more source

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2010
Introduction Imatinib mesylate, a selective Bcr-Abl tyrosine kinase inhibitor, has proved to be most effective therapy of Philadelphia chromosome-positive chronic myelogenous leukemia.
Ćojbašić Irena, Mačukanović-Golubović Lana   +1 more
doaj   +1 more source

Progression, Detection and Remission: Evolution of Chronic Myeloid Leukemia using a three-stage probabilistic model [PDF]

arXiv, 2022
We present a three-stage probabilistic model for the progression of Chronic Myeloid Leukemia (CML), as manifested by the leukemic stem cells, progenitor cells and mature leukemic cells. This progression is captured through the process of cell division and cell mutation, with probabilities of occurrence being assigned to both of them.
arxiv  

A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone [PDF]

, 1996
A 44-year-old man suffering from cytogenetically and molecularly proven Philadelphia translocation-positive chronic myelogenous leukemia in chronic phase was treated with busulfan for 18 months and studied during a follow-up period of 13 years ...
Geurts van Kessel, A.H.M. (Ad), Haanen, C. (C.), Hagemeÿer, A. (A.), Mandigers, C., Mensink, E.J.B.M. (Ewald), Plas, D. (D.) van der, Witte, T. de   +6 more
core   +1 more source

Diagnosis and typing of leukemia using a single peripheral blood cell through deep learning

Cancer Science, Volume 116, Issue 2, Page 533-543, February 2025.
This pioneering research investigates the manner in which cellular morphological responses are linked to the nature of genome information using deep learning. Abstract Leukemia is highly heterogeneous, meaning that different types of leukemia require different treatments and have different prognoses.
Geng Yan, Gao Mingyang, Shi Wei, Liang Hongping, Qin Liyuan, Liu Ailan, Kong Xiaomei, Zhao Huilan, Zhao Juanjuan, Qiang Yan   +9 more
wiley   +1 more source

Bosutinib in the management of chronic myelogenous leukemia

Biologics: Targets & Therapy, 2013
Gunhild Keller-von Amsberg, Philippe SchafhausenDepartment of Hematology and Oncology and, Stem Cell Transplantation and Pulmonology Division, Oncological Center, University Hospital Hamburg-Eppendorf, Hamburg, GermanyAbstract: Bosutinib (SKI-606) is an ...
Keller-von Amsberg G, Schafhausen P
doaj